Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 7, 2013; 19(37): 6144-6155
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6144
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6144
Molecular targeted therapy for hepatocellular carcinoma: Current and future
Jung Woo Shin, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan 682-714, South Korea
Young-Hwa Chung, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul 138-736, South Korea
Author contributions: Shin JW and Chung YH designed this study, collected all the data and wrote the manuscript.
Correspondence to: Young-Hwa Chung, MD, PhD, Professor, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, 86 Asanbyeongwon-gil, Songpa-gu, Seoul 138-736, South Korea. yhchung@amc.seoul.kr
Telephone: +82-2-30103184 Fax: +82-2-4760824
Received: April 2, 2013
Revised: July 18, 2013
Accepted: August 4, 2013
Published online: October 7, 2013
Processing time: 199 Days and 1 Hours
Revised: July 18, 2013
Accepted: August 4, 2013
Published online: October 7, 2013
Processing time: 199 Days and 1 Hours
Core Tip
Core tip: Sorafenib is the first drug to prolong survival of patients with advanced hepatocellular carcinoma (HCC). This advance has shifted the paradigm of systemic treatment for HCC toward molecular targeted therapy. This review aims to summarize the efforts to target molecular components of the signaling pathways that are responsible for the development and progression of HCC and to discuss perspectives on the future direction of research.